3NG5
| Crystal Structure of V30M transthyretin complexed with (-)-epigallocatechin gallate (EGCG) | Descriptor: | (2R,3R)-5,7-dihydroxy-2-(3,4,5-trihydroxyphenyl)-3,4-dihydro-2H-chromen-3-yl 3,4,5-trihydroxybenzoate, GLYCEROL, Transthyretin | Authors: | Miyata, M, Nakamura, T, Ikemizu, S, Chirifu, M, Yamagata, Y, Kai, H. | Deposit date: | 2010-06-11 | Release date: | 2010-07-07 | Last modified: | 2023-11-01 | Method: | X-RAY DIFFRACTION (1.7 Å) | Cite: | Crystal structure of green tea polyphenol(-)-epigallocatechin gallate (EGCG)-transthyretin complex reveals novel binding site distinct from thyroxine binding site Biochemistry, 2010
|
|
3A4F
| Crystal Structure of Human Transthyretin (E54K) | Descriptor: | GLYCEROL, SULFATE ION, Transthyretin | Authors: | Miyata, M, Sato, T, Nakamura, T, Ikemizu, S, Yamagata, Y, Kai, H. | Deposit date: | 2009-07-06 | Release date: | 2009-12-22 | Last modified: | 2023-11-01 | Method: | X-RAY DIFFRACTION (1.99 Å) | Cite: | Role of the glutamic acid 54 residue in transthyretin stability and thyroxine binding Biochemistry, 49, 2010
|
|
3A4E
| Crystal structure of Human Transthyretin (E54G) | Descriptor: | GLYCEROL, SULFATE ION, Transthyretin | Authors: | Miyata, M, Sato, T, Nakamura, T, Ikemizu, S, Yamagata, Y, Kai, H. | Deposit date: | 2009-07-06 | Release date: | 2009-12-22 | Last modified: | 2023-11-01 | Method: | X-RAY DIFFRACTION (1.7 Å) | Cite: | Role of the glutamic acid 54 residue in transthyretin stability and thyroxine binding Biochemistry, 49, 2010
|
|
3A4D
| Crystal structure of Human Transthyretin (wild-type) | Descriptor: | GLYCEROL, SULFATE ION, Transthyretin | Authors: | Miyata, M. | Deposit date: | 2009-07-06 | Release date: | 2009-12-22 | Last modified: | 2023-11-01 | Method: | X-RAY DIFFRACTION (2 Å) | Cite: | Role of the Glutamic Acid 54 Residue in Transthyretin Stability and Thyroxine Binding Biochemistry, 2009
|
|
8Z56
| |
8Z55
| |
8Z58
| |
8Z54
| |
8Z57
| |
8JOK
| |
8JQW
| |
8JNU
| |
8WGT
| Crystal structure of V30M-TTR in complex with compound 7 | Descriptor: | Transthyretin, [4,7-bis(chloranyl)-2-ethyl-1-benzofuran-3-yl]-[3,5-bis(iodanyl)-4-oxidanyl-phenyl]methanone | Authors: | Yokoyama, T. | Deposit date: | 2023-09-22 | Release date: | 2024-05-15 | Last modified: | 2024-05-29 | Method: | X-RAY DIFFRACTION (1.696 Å) | Cite: | Development of Benziodarone Analogues with Enhanced Potency for Selective Binding to Transthyretin in Human Plasma. J.Med.Chem., 67, 2024
|
|
8WGS
| Crystal structure of V30M-TTR in complex with compound 4 | Descriptor: | Transthyretin, [3,5-bis(iodanyl)-4-oxidanyl-phenyl]-(2-ethyl-4-iodanyl-1-benzofuran-3-yl)methanone | Authors: | Yokoyama, T. | Deposit date: | 2023-09-22 | Release date: | 2024-05-15 | Last modified: | 2024-05-29 | Method: | X-RAY DIFFRACTION (1.801 Å) | Cite: | Development of Benziodarone Analogues with Enhanced Potency for Selective Binding to Transthyretin in Human Plasma. J.Med.Chem., 67, 2024
|
|
8WGU
| Crystal structure of V30M-TTR in complex with compound 20 | Descriptor: | Transthyretin, [3,5-bis(iodanyl)-4-oxidanyl-phenyl]-[2-ethyl-4,7-bis(fluoranyl)-1-benzofuran-3-yl]methanone | Authors: | Yokoyama, T. | Deposit date: | 2023-09-22 | Release date: | 2024-05-15 | Last modified: | 2024-05-29 | Method: | X-RAY DIFFRACTION (1.508 Å) | Cite: | Development of Benziodarone Analogues with Enhanced Potency for Selective Binding to Transthyretin in Human Plasma. J.Med.Chem., 67, 2024
|
|
7F4X
| Joint neutron and X-ray crystal structure of the nucleotide-binding domain of Hsp72 in complex with ADP | Descriptor: | ADENOSINE-5'-DIPHOSPHATE, Heat shock 70 kDa protein 1B, MAGNESIUM ION, ... | Authors: | Yokoyama, T, Ostermann, A, Schrader, T.E. | Deposit date: | 2021-06-21 | Release date: | 2022-06-29 | Last modified: | 2024-04-03 | Method: | NEUTRON DIFFRACTION (1.6 Å), X-RAY DIFFRACTION | Cite: | Neutron crystallographic analysis of the nucleotide-binding domain of Hsp72 in complex with ADP. Iucrj, 9, 2022
|
|
8II1
| Crystal structure of V30M-TTR in complex with BID | Descriptor: | Benziodarone, Transthyretin | Authors: | Yokoyama, T. | Deposit date: | 2023-02-24 | Release date: | 2023-06-28 | Last modified: | 2023-11-08 | Method: | X-RAY DIFFRACTION (1.907 Å) | Cite: | Benziodarone and 6-hydroxybenziodarone are potent and selective inhibitors of transthyretin amyloidogenesis. Bioorg.Med.Chem., 90, 2023
|
|
8II4
| Crystal structure of V30M-TTR in complex with 6-hydroxy BBM | Descriptor: | Transthyretin, [3,5-bis(bromanyl)-4-oxidanyl-phenyl]-(2-ethyl-6-oxidanyl-1-benzofuran-3-yl)methanone | Authors: | Yokoyama, T. | Deposit date: | 2023-02-24 | Release date: | 2023-06-28 | Last modified: | 2024-05-29 | Method: | X-RAY DIFFRACTION (1.499 Å) | Cite: | Benziodarone and 6-hydroxybenziodarone are potent and selective inhibitors of transthyretin amyloidogenesis. Bioorg.Med.Chem., 90, 2023
|
|
8II3
| Crystal structure of V30M-TTR in complex with 6-hydroxy BID | Descriptor: | Transthyretin, [3,5-bis(iodanyl)-4-oxidanyl-phenyl]-(2-ethyl-6-oxidanyl-1-benzofuran-3-yl)methanone | Authors: | Yokoyama, T. | Deposit date: | 2023-02-24 | Release date: | 2023-06-28 | Last modified: | 2024-05-29 | Method: | X-RAY DIFFRACTION (1.399 Å) | Cite: | Benziodarone and 6-hydroxybenziodarone are potent and selective inhibitors of transthyretin amyloidogenesis. Bioorg.Med.Chem., 90, 2023
|
|
8II2
| Crystal structure of V30M-TTR in complex with BBM | Descriptor: | CALCIUM ION, Transthyretin, [3,5-bis(bromanyl)-4-oxidanyl-phenyl]-(2-ethyl-1-benzofuran-3-yl)methanone | Authors: | Yokoyama, T. | Deposit date: | 2023-02-24 | Release date: | 2023-06-28 | Last modified: | 2024-05-29 | Method: | X-RAY DIFFRACTION (1.798 Å) | Cite: | Benziodarone and 6-hydroxybenziodarone are potent and selective inhibitors of transthyretin amyloidogenesis. Bioorg.Med.Chem., 90, 2023
|
|
8IG1
| Crystal structure of wild-type transthyretin in complex with rafoxanide | Descriptor: | SODIUM ION, Transthyretin, ~{N}-[3-chloranyl-4-(4-chloranylphenoxy)phenyl]-3,5-bis(iodanyl)-2-oxidanyl-benzamide | Authors: | Yokoyama, T. | Deposit date: | 2023-02-20 | Release date: | 2023-08-16 | Last modified: | 2023-11-15 | Method: | X-RAY DIFFRACTION (1.451 Å) | Cite: | Rafoxanide, a salicylanilide anthelmintic, interacts with human plasma protein transthyretin. Febs J., 290, 2023
|
|
8W42
| X-ray crystal structure of V30M-TTR in complex with resveratrol | Descriptor: | RESVERATROL, SODIUM ION, Transthyretin | Authors: | Yokoyama, T. | Deposit date: | 2023-08-23 | Release date: | 2023-11-22 | Last modified: | 2023-12-06 | Method: | X-RAY DIFFRACTION (1.45 Å) | Cite: | Resveratrol Derivatives Inhibit Transthyretin Fibrillization: Structural Insights into the Interactions between Resveratrol Derivatives and Transthyretin. J.Med.Chem., 66, 2023
|
|
8W44
| X-ray crystal structure of V30M-TTR in complex with oxyresveratrol | Descriptor: | SODIUM ION, Transthyretin, trans-oxyresveratrol | Authors: | Yokoyama, T. | Deposit date: | 2023-08-23 | Release date: | 2023-11-22 | Last modified: | 2023-12-06 | Method: | X-RAY DIFFRACTION (1.399 Å) | Cite: | Resveratrol Derivatives Inhibit Transthyretin Fibrillization: Structural Insights into the Interactions between Resveratrol Derivatives and Transthyretin. J.Med.Chem., 66, 2023
|
|
8W46
| X-ray crystal structure of V30M-TTR in complex with pterostilbene | Descriptor: | Pterostilbene, SODIUM ION, Transthyretin | Authors: | Yokoyama, T. | Deposit date: | 2023-08-23 | Release date: | 2023-11-22 | Last modified: | 2023-12-06 | Method: | X-RAY DIFFRACTION (1.35 Å) | Cite: | Resveratrol Derivatives Inhibit Transthyretin Fibrillization: Structural Insights into the Interactions between Resveratrol Derivatives and Transthyretin. J.Med.Chem., 66, 2023
|
|
8W43
| X-ray crystal structure of V30M-TTR in complex with piceatannol | Descriptor: | PICEATANNOL, SODIUM ION, Transthyretin | Authors: | Yokoyama, T. | Deposit date: | 2023-08-23 | Release date: | 2023-11-22 | Last modified: | 2023-12-06 | Method: | X-RAY DIFFRACTION (1.302 Å) | Cite: | Resveratrol Derivatives Inhibit Transthyretin Fibrillization: Structural Insights into the Interactions between Resveratrol Derivatives and Transthyretin. J.Med.Chem., 66, 2023
|
|